Hormonal Contraception and HIV Risk: Understanding the ECHO trial

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.

Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.

The webinar featured:

Beth Schlachter, Executive Director, FP2020
Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
Tamar Abrams, Communications Director, FP2020

You may view the webinar here.

HIV Vaccine Research and Development Pipeline: 2019 Supplement

A slide deck overview of what’s happening in HIV vaccine research now.

Oral PrEP Enrollment Snapshot

For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.

From Research to Roll Out: Comparing oral PrEP to the dapivirine ring

These slides provide an overview of the process that takes an HIV prevention product from the final phases of research into the real world where it’s broadly available. Also included is a comparison of findings from research on the dapivirine ring and oral PrEP at key points along the process.

A PDF version is also available.

PrEP 101 Presentation from US Women & PrEP Working Group

Created by the US Women and PrEP Working Group, this PowerPoint is intended to help make quality, basic presentations on PrEP to community members.

Harnessing Antibodies for HIV Prevention and Treatment

John Mascola of the NIH Vaccine Research Center spoke about harnessing antibodies for HIV prevention and treatment. The recording includes discussion with webinar participants. For more background, click here to view his CROI plenary session.

EATG 2015 Webinar 1: An update on PrEP in Europe

This series of three webinars, hosted jointly by EATG and AVAC, was designed to prepare and update EATG members for a special meeting on new developments in prevention January 2016 in Brussels. The first webinar addressed the latest updates on PrEP in Europe. Speakers: Dr Valentina Cambiano of University College London, Daniela Rojas Castro of AIDES and Dr Anastasia Pharris of the European Centre for Disease Prevention and Control (ECDC).

Follow the Money: Knowns and unknowns when it comes to cash transfers and financial incentives to improve health in people living with and/or at risk of HIV

This webinar featured Wafaa El-Sadr, principal investigator of HPTN 065, which evaluated the use of cash incentives in improving outcomes for people living with HIV in the United States.

These were useful talks from CROI and excerpts from AVAC Report 2014/15 as preparation for our webinar:

CROI Webcast: Effect of Financial Incentives on Linkage to Care and Viral Suppression: HPTN 065
CROI Webcast: Social Protection, Financial Incentives and Prevention of HIV
Excerpts from AVAC Report on target setting and targets that worked

Demanding Clarity on PrEP: Understanding recent data on oral PrEP

This webinar featured Jean-Michel Molina of the French research agency ANRS and Sheena McCormack of the UK Medical Research Council discussing the data from the IPERGAY and PROUD studies, respectively. Both trials evaluated oral TDF/FTC (brand name Truvada) as PrEP in gay men and other men who have sex with men, and both reported high levels of protection against HIV acquisition. PROUD prescribed a daily pill regimen; IPERGAY asked trial participants to follow an “event driven” regimen that involved a sequence of doses before and after sex. IPERGAY participants took an average of four doses per week—comparable to the estimated protective dose required in trials of daily oral PrEP.

New Frontiers in HIV Prevention, Treatment and Cure: An advocate’s webinar on passive immunization

This webinar focused on “passive immunization”—a scientific term for an expanding area of research that’s highly relevant to treatment, prevention and cure work. There are trials in humans happening in many regions of the world—and data are beginning to come in that advocates need to understand, analyze and consider. The webinar featured Dr. Sarah Schlesinger (Rockefeller University) who provided an overview of recent developments across the field including new published data.